TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Total Body Skin Examination on Skin Cancer Detection
Brief Summary: This will be a study where all patients will undergo a two-step procedure:

Step 1 - Physicians examine the problem area of skin ONLY and record result. Step 2 - Physicians perform TBSE and record result. Eventual lesions suggestive of melanoma and non-melanoma skin cancers will be recorded after step 1 or step 2 examination and will be finally biopsied and histopathologically diagnosed. Exceptions to biopsy may include patients with multiple non-melanoma skin cancers (e.g. actinic keratoses or basal cell carcinomas).

Each center will be provided with an electronic data sheet for patients record, or alternatively, with a paper record form.

Endpoints of the study are new parameters concerning the standard of care for skin cancer screening. We expect to conclude that TBSE enables clinicians discovering an increased number of skin cancers thus resulting in earlier detection.


Options:
A: N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Office visit | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Evisit | Intervention Type: OTHER; Name: Evisit; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Office visit; Assigned to Arm(s): 1
C: Arm Label: Skin cancer screening; Type: OTHER; Interventions: Other: Inspection of covered areas | Intervention Type: OTHER; Name: Inspection of covered areas; Assigned to Arm(s): Skin cancer screening
D: Arm Label: Vismodegib 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Vismodegib 150 mg | Intervention Type: DRUG; Name: Vismodegib 150 mg; Assigned to Arm(s): Vismodegib 150 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Total Body Skin Examination on Skin Cancer Detection
Brief Summary: This will be a study where all patients will undergo a two-step procedure:

Step 1 - Physicians examine the problem area of skin ONLY and record result. Step 2 - Physicians perform TBSE and record result. Eventual lesions suggestive of melanoma and non-melanoma skin cancers will be recorded after step 1 or step 2 examination and will be finally biopsied and histopathologically diagnosed. Exceptions to biopsy may include patients with multiple non-melanoma skin cancers (e.g. actinic keratoses or basal cell carcinomas).

Each center will be provided with an electronic data sheet for patients record, or alternatively, with a paper record form.

Endpoints of the study are new parameters concerning the standard of care for skin cancer screening. We expect to conclude that TBSE enables clinicians discovering an increased number of skin cancers thus resulting in earlier detection.


Options:
A: Intervention Type: DRUG; Name: imiquimod; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A
B: Arm Label: Vismodegib 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Vismodegib 150 mg | Intervention Type: DRUG; Name: Vismodegib 150 mg; Assigned to Arm(s): Vismodegib 150 mg
C: Arm Label: Skin cancer screening; Type: OTHER; Interventions: Other: Inspection of covered areas | Intervention Type: OTHER; Name: Inspection of covered areas; Assigned to Arm(s): Skin cancer screening
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Continuous Intravenous Ketorolac for Postoperative Pain in Laparoscopic Donor Nephrectomy: a Double Blinded Randomized Placebo Controlled Trial.
Brief Summary: The purpose of this study is to determine whether continuous intravenous ketorolac infusion reduces pain in patients who are having laparoscopic surgery to donate a kidney.


Options:
A: Arm Label: Multimodal; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen, Drug: Gabapentin, Drug: Paracetamol | Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine, Drug: Paracetamol | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Multimodal | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Multimodal | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Morphine, Multimodal
B: Arm Label: Active Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Active ASA | Arm Label: Active Clonidine and Placebo ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Placebo ASA | Arm Label: Placebo Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Placebo Clonidine, Drug: Active ASA | Arm Label: Placebo Clonidine and Placebo ASA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Clonidine, Drug: Placebo ASA | Intervention Type: DRUG; Name: Active Clonidine; Assigned to Arm(s): Active Clonidine and Active ASA, Active Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Placebo Clonidine; Assigned to Arm(s): Placebo Clonidine and Active ASA, Placebo Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Active ASA; Assigned to Arm(s): Active Clonidine and Active ASA, Placebo Clonidine and Active ASA | Intervention Type: DRUG; Name: Placebo ASA; Assigned to Arm(s): Active Clonidine and Placebo ASA, Placebo Clonidine and Placebo ASA
C: Arm Label: Ketorolac; Type: EXPERIMENTAL; Interventions: Drug: Ketorolac | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ketorolac; Assigned to Arm(s): Ketorolac | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ketorolac; Type: EXPERIMENTAL; Interventions: Drug: Ketorolac | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ketorolac; Assigned to Arm(s): Ketorolac | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III, Open-Label, Multicenter International Study to Evaluate the Efficacy and Safety of an Octreotide Implant vs. Sandostatin LAR Depot in Patients With Acromegaly
Brief Summary: Evaluate the efficacy, safety and tolerability of the octreotide implant in patients with acromegaly that were previously treated with octreotide depot.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Octreotide Implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sandostatin LAR Depot | Intervention Type: DRUG; Name: Octreotide Implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sandostatin LAR Depot; Assigned to Arm(s): 2
B: Arm Label: Sandostatin s.c. (Octreotide); Type: EXPERIMENTAL; Interventions: Drug: Pasireotide (SOM230), Octreotide (Sandostatin) | Arm Label: Pasireotide (SOM230); Type: EXPERIMENTAL; Interventions: Drug: Pasireotide (SOM230), Octreotide (Sandostatin) | Intervention Type: DRUG; Name: Pasireotide (SOM230), Octreotide (Sandostatin); Assigned to Arm(s): Pasireotide (SOM230), Sandostatin s.c. (Octreotide)
C: Arm Label: Lanreotide autogel 120 mg; Type: EXPERIMENTAL; Interventions: Drug: Lanreotide autogel 120 mg | Intervention Type: DRUG; Name: Lanreotide autogel 120 mg; Assigned to Arm(s): Lanreotide autogel 120 mg
D: Arm Label: Pasireotide LAR 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Pasireotide | Arm Label: Pasireotide LAR 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Pasireotide | Arm Label: Control arm (octreotide or lanreotide); Type: ACTIVE_COMPARATOR; Interventions: Drug: octreotide LAR 30mg, Drug: lanreotide ATG 120mg | Intervention Type: DRUG; Name: Pasireotide; Assigned to Arm(s): Pasireotide LAR 40 mg, Pasireotide LAR 60 mg | Intervention Type: DRUG; Name: octreotide LAR 30mg; Assigned to Arm(s): Control arm (octreotide or lanreotide) | Intervention Type: DRUG; Name: lanreotide ATG 120mg; Assigned to Arm(s): Control arm (octreotide or lanreotide)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Controlled Clinical Trial of the Use of Autologous Bone Marrow Derived Progenitor Cells to Salvage Myocardium in Patients With Acute Anterior Myocardial Infarction
Brief Summary: Study hypothesis :

The purpose of this study is to determine whether Intracoronary infusion of autologous bone marrow derived progenitor cells to patients undergoing primary angioplasty for acute anterior myocardial infarction will lead to an improvement in cardiac function greater than that seen by placebo alone.

Aims

* To demonstrate that it is safe and feasible to deliver autologous bone marrow derived stem cells within hours of the primary angioplasty procedure
* To demonstrate the effects of autologous bone marrow derived stem cells on cardiac function using cardiac MRI (or cardiac CT), echocardiography and left ventriculography.
* To demonstrate the effect of autologous bone marrow derived stem cells in addition to standard care leads to improvement in cardiac function compared to patients saline(placebo) and standard care.


Options:
A: Arm Label: Ixmyelocel-T; Type: EXPERIMENTAL; Interventions: Biological: Ixmyelocel-T | Arm Label: Vehicle Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Vehicle Control | Intervention Type: BIOLOGICAL; Name: Ixmyelocel-T; Assigned to Arm(s): Ixmyelocel-T | Intervention Type: OTHER; Name: Vehicle Control; Assigned to Arm(s): Vehicle Control
B: Arm Label: Intracoronary; Type: EXPERIMENTAL; Interventions: Other: Bone marrow derived progenitor cells or placebo infusion | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo infusion | Intervention Type: OTHER; Name: Bone marrow derived progenitor cells or placebo infusion; Assigned to Arm(s): Intracoronary | Intervention Type: OTHER; Name: Placebo infusion; Assigned to Arm(s): Placebo
C: Arm Label: Experimental: Human (aMBMC); Type: EXPERIMENTAL; Interventions: Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) | Arm Label: Placebo:Lactated Ringer's Solution (LRS); Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactated Ringer's Solution | Intervention Type: DRUG; Name: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC); Assigned to Arm(s): Experimental: Human (aMBMC) | Intervention Type: DRUG; Name: Lactated Ringer's Solution; Assigned to Arm(s): Placebo:Lactated Ringer's Solution (LRS)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: C-Cure | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: C-Cure; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Controlled Clinical Trial of the Use of Autologous Bone Marrow Derived Progenitor Cells to Salvage Myocardium in Patients With Acute Anterior Myocardial Infarction
Brief Summary: Study hypothesis :

The purpose of this study is to determine whether Intracoronary infusion of autologous bone marrow derived progenitor cells to patients undergoing primary angioplasty for acute anterior myocardial infarction will lead to an improvement in cardiac function greater than that seen by placebo alone.

Aims

* To demonstrate that it is safe and feasible to deliver autologous bone marrow derived stem cells within hours of the primary angioplasty procedure
* To demonstrate the effects of autologous bone marrow derived stem cells on cardiac function using cardiac MRI (or cardiac CT), echocardiography and left ventriculography.
* To demonstrate the effect of autologous bone marrow derived stem cells in addition to standard care leads to improvement in cardiac function compared to patients saline(placebo) and standard care.


Options:
A: Arm Label: Intracoronary; Type: EXPERIMENTAL; Interventions: Other: Bone marrow derived progenitor cells or placebo infusion | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo infusion | Intervention Type: OTHER; Name: Bone marrow derived progenitor cells or placebo infusion; Assigned to Arm(s): Intracoronary | Intervention Type: OTHER; Name: Placebo infusion; Assigned to Arm(s): Placebo
B: Arm Label: The treatment group; Type: EXPERIMENTAL; Interventions: Procedure: Intracoronary injection of autologous bone marrow mononuclear cells | Arm Label: the control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Intracoronary injection of autologous bone marrow mononuclear cells; Assigned to Arm(s): The treatment group
C: Arm Label: BMSCs transplantation; Type: EXPERIMENTAL; Interventions: Procedure: Hypoxia-stressed BMSCs transplantation to cure MI | Arm Label: No BMSCs transplantation; Type: SHAM_COMPARATOR; Interventions: Procedure: Hypoxia-stressed BMSCs transplantation to cure MI | Intervention Type: PROCEDURE; Name: Hypoxia-stressed BMSCs transplantation to cure MI; Assigned to Arm(s): BMSCs transplantation, No BMSCs transplantation
D: Intervention Type: DRUG; Name: G-CSF with/without darbepoetin, peripheral blood stem cell infusion; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intramyocardial Delivery of Autologous Bone Marrow Cells in Patients With Heart Failure Due to Dilated Cardiomyopathy
Brief Summary: This study is designed to assess the safety and tolerability of Cardiac Repair Cells (CRCs) compared to standard-of-care in patients with dilated cardiomyopathy (DCM).


Options:
A: Arm Label: Ixmyelocel-T; Type: EXPERIMENTAL; Interventions: Biological: Ixmyelocel-T | Arm Label: Standard of Care; Type: OTHER; Interventions: Other: Standard of Care | Intervention Type: BIOLOGICAL; Name: Ixmyelocel-T; Assigned to Arm(s): Ixmyelocel-T | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Standard of Care
B: Arm Label: Experimental: Human (aMBMC); Type: EXPERIMENTAL; Interventions: Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) | Arm Label: Placebo:Lactated Ringer's Solution (LRS); Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactated Ringer's Solution | Intervention Type: DRUG; Name: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC); Assigned to Arm(s): Experimental: Human (aMBMC) | Intervention Type: DRUG; Name: Lactated Ringer's Solution; Assigned to Arm(s): Placebo:Lactated Ringer's Solution (LRS)
C: Arm Label: Autologous hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Autologous hMSCs | Arm Label: Allogeneic hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Allogeneic hMSCs | Intervention Type: BIOLOGICAL; Name: Autologous hMSCs; Assigned to Arm(s): Autologous hMSCs | Intervention Type: BIOLOGICAL; Name: Allogeneic hMSCs; Assigned to Arm(s): Allogeneic hMSCs
D: Arm Label: Treated Group; Type: EXPERIMENTAL; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Intervention Type: PROCEDURE; Name: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation; Assigned to Arm(s): Control Group, Treated Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial of a Bowel Cancer Screening Decision Aid for Adults With Low Education and Literacy
Brief Summary: The purpose of this study is to evaluate a decision aid (written information booklet designed to facilitate informed decision making) to help people aged 55-64 years, with low levels of education and literacy, make an informed choice about bowel cancer screening, using faecal occult blood testing.


Options:
A: Intervention Type: OTHER; Name: informational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: survey administration; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Bowel cancer screening decision aid | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Bowel cancer screening decision aid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Other: Australian Government Bowel Cancer Screening booklet | Intervention Type: OTHER; Name: Bowel cancer screening decision aid; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Bowel cancer screening decision aid; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Australian Government Bowel Cancer Screening booklet; Assigned to Arm(s): 3
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Patient video decision aid & telephone coaching | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Printed educational brochure | Intervention Type: BEHAVIORAL; Name: Patient video decision aid & telephone coaching; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Printed educational brochure; Assigned to Arm(s): 2
D: Arm Label: ADAPT tool; Type: EXPERIMENTAL; Interventions: Behavioral: ADAPT tool | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ADAPT tool; Assigned to Arm(s): ADAPT tool

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial of a Bowel Cancer Screening Decision Aid for Adults With Low Education and Literacy
Brief Summary: The purpose of this study is to evaluate a decision aid (written information booklet designed to facilitate informed decision making) to help people aged 55-64 years, with low levels of education and literacy, make an informed choice about bowel cancer screening, using faecal occult blood testing.


Options:
A: Arm Label: Chest Pain Choice Decision Aid; Type: ACTIVE_COMPARATOR; Interventions: Other: Chest Pain Choice Decision Aid | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Chest Pain Choice Decision Aid; Assigned to Arm(s): Chest Pain Choice Decision Aid
B: Arm Label: Decision Aid; Type: EXPERIMENTAL; Interventions: Other: Decision Aid | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Decision Aid; Assigned to Arm(s): Decision Aid
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Bowel cancer screening decision aid | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Bowel cancer screening decision aid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Other: Australian Government Bowel Cancer Screening booklet | Intervention Type: OTHER; Name: Bowel cancer screening decision aid; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Bowel cancer screening decision aid; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Australian Government Bowel Cancer Screening booklet; Assigned to Arm(s): 3
D: Arm Label: Absolute risk reduction information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Absolute risk reduction | Arm Label: Prolongation of life information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prolongation of life | Intervention Type: BEHAVIORAL; Name: Absolute risk reduction; Assigned to Arm(s): Absolute risk reduction information | Intervention Type: BEHAVIORAL; Name: Prolongation of life; Assigned to Arm(s): Prolongation of life information

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG)
Brief Summary: The principal objective of this multicenter, randomized, placebo-controlled trial is to evaluate whether treatment with nortriptyline will improve gastroparesis symptoms compared with placebo.


Options:
A: Arm Label: Nortriptyline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nortriptyline Hydrochloride | Arm Label: Placebo (for nortriptyline); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for nortriptyline) | Intervention Type: DRUG; Name: Nortriptyline Hydrochloride; Assigned to Arm(s): Nortriptyline | Intervention Type: DRUG; Name: Placebo (for nortriptyline); Assigned to Arm(s): Placebo (for nortriptyline)
B: Intervention Type: DRUG; Name: topical lidocaine + oral desipramine, and/or placebo; Assigned to Arm(s): N/A
C: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: [S,S]-Reboxetine | Arm Label: 4; Type: SHAM_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: [S,S]-Reboxetine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: [S,S]-Reboxetine | Intervention Type: DRUG; Name: [S,S]-Reboxetine; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: [S,S]-Reboxetine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: [S,S]-Reboxetine; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Centre, Randomized, Double Blind Cross-over Study to Assess the Non-inferiority of GW685698X 200mcg Once Daily and 100mcg Twice Daily in Adult and Adolescent Patients With Asthma
Brief Summary: The purpose of this study is to compare once and twice daily GW685698 in asthma


Options:
A: Arm Label: Fluticasone furoate/GW642444; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/GW642444 | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate | Intervention Type: DRUG; Name: Fluticasone Furoate/GW642444; Assigned to Arm(s): Fluticasone furoate/GW642444 | Intervention Type: DRUG; Name: Fluticasone furoate; Assigned to Arm(s): fluticasone furoate
B: Arm Label: GW685698X; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): GW685698X
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: GW685698X 200mcg,GW685698X 200mcg and 400mcg | Intervention Type: DRUG; Name: GW685698X 200mcg,GW685698X 200mcg and 400mcg; Assigned to Arm(s): Arm 1
D: Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) MDI | Arm Label: F/SC DPI 250/50 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol (F/SC) DPI | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) MDI; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol (F/SC) DPI; Assigned to Arm(s): F/SC DPI 250/50 mcg BID

Answer: B